Single-Use Bioreactors Market to Reach USD 9.12 Billion by 2033 | 8.8% CAGR | North America Leads with 40% Share | Key Players: ABEC, Thermo Fisher, Sartorius, Merck, Cytiva, PBS Biotech, Eppendorf, Getinge

Single-Use Bioreactors Market

The Global Single-Use Bioreactors Market was valued at US$ 4.30 billion in 2023, increased to US$ 4.64 billion in 2024, and is projected to reach US$ 9.12 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033. This growth is primarily driven by the rising demand for biologics, vaccines, and advanced cell and gene therapies, coupled with the rapid expansion of contract development and manufacturing organizations (CDMOs) and biopharmaceutical R&D centers worldwide. The increasing focus on flexible, scalable, and contamination-free production processes has made single-use bioreactors a preferred choice across research laboratories, pilot plants, and large-scale manufacturing facilities. These systems offer significant operational benefits, including reduced turnaround time, lower cleaning and validation costs, and enhanced sterility assurance, making them ideal for multiproduct and small-batch production environments.

Technological innovations, such as integrated sensor technologies, automated control systems, and the introduction of large-volume disposable bioreactors (up to 6,000 L), are improving process efficiency, reproducibility, and safety. Furthermore, the shift toward modular biomanufacturing and the ability to rapidly scale production for emerging therapies - particularly mRNA vaccines and cell-based treatments are fueling adoption across the biopharma landscape. Sustainability is becoming a major trend in the market, with companies investing in eco-friendly and recyclable single-use materials to minimize plastic waste and align with green manufacturing practices. The continued development of hybrid bioreactor systems, combining stainless steel and single-use components, also reflects a growing trend toward operational flexibility and cost optimization.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/single-use-bioreactors-market?Juli

Recent Developments:

✅ October 2025: A leading bioprocessing solutions provider launched a next-generation single-use bioreactor platform with expanded real-time process analytics and automated control features, enhancing reproducibility and reducing human intervention.

✅ August 2025: A major life sciences OEM expanded its disposable bioreactor portfolio to include larger volume single-use systems (2,000-6,000 L), targeting commercial-scale biologics and vaccine production.

✅ June 2025: A global CDMO announced installation of integrated single-use bioreactor systems in a newly commissioned biologics manufacturing facility, enabling rapid scale-up for monoclonal antibodies and cell therapies.

✅ April 2025: A biotechnology equipment company introduced bioreactor sensor kits with enhanced multi-parameter monitoring (pH, dissolved oxygen, metabolites) optimized for single-use systems to improve upstream process control.

✅ March 2025: Several biopharma startups and research institutions adopted automated single-use bioreactor workflows integrated with digital twin and AI-based predictive control tools for accelerated vaccine development campaigns.

Mergers & Acquisitions:

✅ 2025: A leading U.S. life sciences equipment manufacturer acquired a single-use bioprocessing technology provider to expand its end-to-end biomanufacturing solutions portfolio, strengthening its global position in the bioprocessing ecosystem.

✅ May 2024: Novo Holdings acquired a controlling stake in Single Use Support, a bioprocess fluid management company, to enhance its single-use systems supply chain and improve scalability for biologics manufacturing.

✅ 2023: Danaher Corporation completed its merger with the life sciences business of Pall Corporation, adding the iCELLis single-use bioreactor platform and other technologies to its Cytiva product line, bolstering its upstream processing portfolio.

✅ 2025: Thermo Fisher Scientific announced the acquisition of Solventum's purification and filtration business to complement its single-use technology offerings and strengthen its biologics production and filtration capabilities.

✅ Ongoing Trend: Major bioprocessing companies continue to pursue strategic mergers, acquisitions, and partnerships to broaden their single-use bioreactor portfolios, integrate advanced process control systems, and expand their global manufacturing footprint.

Buy Now & Unlock 360° Market Intelligence:-https://www.datamintelligence.com/buy-now-page?report=single-use-bioreactors-market?Juli

Key Players:
ABEC | Thermo Fisher Scientific | Sartorius | Merck KGaA | Cytiva | PBS Biotech | Eppendorf | Getinge

Key Highlights:

• ABEC - Holds a 17% market share, driven by its strong portfolio of large-scale single-use bioreactors (up to 6,000 L) and customizable bioprocess solutions tailored for commercial biologics and vaccine production.

• Thermo Fisher Scientific - Holds a 16% market share, supported by its comprehensive range of single-use bioprocessing technologies and integrated automation systems enhancing biomanufacturing efficiency.

• Sartorius - Holds a 15% market share, fueled by innovations in scalable single-use bioreactors and advanced control systems for cell culture and biologics manufacturing.

• Merck KGaA - Holds a 13% market share, driven by its Mobius® single-use bioreactor platform and end-to-end bioprocess solutions designed for flexibility and contamination-free processing.

• Cytiva - Holds a 12% market share, leveraging its strong Cytiva (formerly GE Healthcare Life Sciences) portfolio with cutting-edge single-use technologies and integrated bioprocess workflows.

• PBS Biotech - Holds a 10% market share, recognized for its innovative vertical-wheel bioreactor design optimized for stem cell and cell therapy manufacturing.

• Eppendorf - Holds an 9% market share, specializing in small- to mid-scale bioreactors and benchtop single-use systems widely adopted in research and process development labs.

• Getinge - Holds an 8% market share, supported by its bioprocessing equipment and automation technologies integrated into single-use biomanufacturing environments.

Market Segmentation:

➥ By Product, single-use bioreactor systems dominate the market with a 40% share, driven by their widespread use in biologics and vaccine manufacturing due to benefits like reduced contamination risk, faster setup times, and lower operational costs. Single-use media bags account for 25%, playing a vital role in storage, mixing, and media transfer applications across small and large-scale facilities. Single-use filtration assemblies hold a 20% share, supported by their integration in upstream and downstream processing for ensuring sterility and product purity. The remaining 15% includes other accessories such as connectors, tubing sets, and sensors that complement disposable bioprocessing workflows.

➥ By Type, stirred-tank single-use bioreactors lead with a 50% share, favored for their scalability, process control precision, and suitability for mammalian cell culture and monoclonal antibody production. Wave-induced single-use bioreactors hold a 30% share, popular for pilot-scale and clinical manufacturing due to gentle mixing and ease of use. Bubble column single-use bioreactors represent 20%, gaining traction in microbial and stem cell culture applications that demand cost efficiency and high oxygen transfer rates.

➥ By Molecule Type, monoclonal antibodies (mAbs) dominate with a 45% share, reflecting high production demand for therapeutic antibodies in oncology and autoimmune diseases. Vaccines hold 25%, boosted by global immunization drives and pandemic preparedness efforts. Stem cells and gene-modified cells collectively account for 20%, driven by accelerating adoption of cell and gene therapies. The remaining 10% includes other molecules such as enzymes and recombinant proteins used in R&D and specialty therapeutics.

➥ By Cell Type, mammalian cells dominate with a 55% share, as they are the preferred choice for producing complex biologics, antibodies, and recombinant proteins. Bacterial cells hold 20%, used primarily for producing enzymes and plasmid DNA. Yeast cells account for 15%, benefiting from increasing applications in vaccine and recombinant protein production. Other cell types, including insect and plant cells, contribute 10%, supported by emerging biomanufacturing platforms for niche and high-value biologics.

Regional Insights:

North America dominates the global single-use bioreactors market, holding a 40% share in 2024, driven by strong biopharmaceutical infrastructure, the rapid expansion of biologics and cell therapy manufacturing, and significant adoption of single-use systems by CDMOs and biomanufacturers. The United States remains the regional leader, supported by high R&D investments, advanced automation integration, and a growing focus on flexible, modular biomanufacturing facilities.

Europe follows with a 30% market share, propelled by robust biopharma production in countries such as Germany, Switzerland, and the United Kingdom. The region's emphasis on sustainability, coupled with regulatory support for disposable technologies and cost-efficient manufacturing, continues to drive adoption across both established and emerging biomanufacturing sites.

Asia-Pacific is the fastest-growing region, accounting for 20% of the market in 2024 and projected to expand rapidly through 2033. Growth is driven by strong investments in biologics manufacturing, government support for local biopharma capacity building, and the proliferation of new CDMOs in China, India, South Korea, and Singapore. The region's growing demand for biosimilars and vaccines further boosts the adoption of single-use bioreactors.

Latin America holds a 6% share, with increasing biomanufacturing activities in Brazil and Mexico, supported by growing healthcare expenditure and efforts to localize biologics production.

Speak to Our Analyst and Get Customization in the report as per your requirements:-https://www.datamintelligence.com/customize/single-use-bioreactors-market?Juli

Market Dynamics:

Driver: Growing Demand for Biologics
The rising demand for biologics is a key growth driver for the single-use bioreactors market. Biopharmaceutical companies developing complex therapies require production systems that are flexible, scalable, and contamination-free. Single-use bioreactors (SUBs) meet these needs by minimizing cross-contamination risk, enabling rapid scale-up, and avoiding the high capital and maintenance costs associated with traditional stainless-steel systems. The proliferation of monoclonal antibody (mAb) therapeutics, particularly in oncology and immunology, has prompted CDMOs and biomanufacturers to adopt SUBs optimized for mammalian cell cultures. Larger-scale SUBs, such as 5,000 L systems, now bridge the gap between lab-scale and commercial-scale production, allowing companies to adjust capacity based on demand fluctuations without extensive infrastructure changes. Furthermore, the growing role of CDMOs in supporting emerging biotech firms and large pharmaceutical companies has accelerated SUB adoption. Industry data indicates that over 50% of SUB deals involve stirred-tank configurations, underscoring their alignment with commercial biologics production. Overall, the surge in biologics is driving the choice of single-use systems for speed, flexibility, and cost efficiency, fueling sustained market growth.

Restraint: Extractables & Leachables Risk
A significant challenge for the SUB market is the risk of extractables and leachables from disposable components such as plastic films, tubing, and connectors. Chemical compounds released into the cell culture can compromise product quality, safety, and regulatory compliance, especially for sensitive biologics like monoclonal antibodies and cell therapies. This concern necessitates rigorous validation and control measures, increasing development costs and slowing adoption. Consequently, manufacturers may be cautious about scaling up single-use systems unless they can ensure consistent containment of extractables and leachables, presenting a key restraint to market expansion.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape

✅ Sustainability Impact Analysis

✅ KOL / Stakeholder Insights

✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots

✅ Market Volatility & Emerging Risks Analysis

✅ Quarterly Industry Report Updated

✅ Live Market & Pricing Trends

✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.